Figure S1. Box plot for the simulated target saturation over time after DARA SC monotherapy or DARA IV monotherapy.

DARA, daratumumab; SC, subcutaneous; IV, intravenous.

Note: Black arrows represent dose events.



Figure S2. Simulated total clearance and linear clearance versus time profiles for DARA SC and DARA IV for monotherapy dosing schedule[a] based on typical values of final model parameters.

DARA, daratumumab; SC, subcutaneous; IV, intravenous.

Note: Black arrows represent dose events.

[a]Approved dose schedule consisted of weekly administration for 8 weeks (8 doses), every 2 weeks for 16 weeks (8 doses), and every 4 weeks thereafter (eg, 8 doses).



Figure S3. Simulated DARA $C_{troughs}$ after 6 weekly doses of DARA SC 1,800 mg monotherapy or combination therapies.

DARA, daratumumab; C_{trough}, predicted trough concentration; SC subcutaneous; D-VRd, daratumumab SC plus bortezomib/lenalidomide/dexamethasone; D-VMP, DARA SC plus bortezomib/melphalan/prednisone; D-Rd, DARA SC plus lenalidomide/dexamethasone.



Figure S4. ORR in relation to DARA maximum C_{trough} (by Quartiles) at the end of weekly dosing for combination therapies.

ORR, overall response rate; DARA, daratumumab; C_{trough}, predicted trough concentration; D-VRd, daratumumab SC plus bortezomib/lenalidomide/dexamethasone; D-VMP, DARA SC plus bortezomib/melphalan/prednisone; D-Rd, DARA SC plus lenalidomide/dexamethasone; SC subcutaneous; Q, quartile.

Note: The quartiles for maximum $C_{troughs}$ are: Q1 (0.1-428 µg/mL), Q2 (428-548 µg/mL), Q3 (548-662 µg/mL), and Q4 (662-1210 µg/mL).